Drug-induced hypersalivation – what treatment options are available?

This Medicines Q&A summarises published studies or case reports concerning the pharmacological treatment of drug-induced hypersalivation (drooling or sialorrhoea), particularly hypersalivation caused by clozapine.   Amisulpride Atropine Benzatropine Biperiden Botulinum A toxin Bupropion Clonidine Clozapine Glycopyrronium Guanfacine Hyoscine butylbromide Hyoscine hydrobromide Ipratropium Lofexidine Metoclopramide Moclobemide Oxybutynin Pirenzepine Propantheline Q&A Quetiapine Sulpiride Trihexyphenidyl

Medicine Compliance Aid Stability

Pro-Banthine · Archimedes Pharma UK Ltd

Archimedes Pharma UK Ltd
Tablets s/c 15mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from moisture
No special precautions for storage
4th November 2015

Lactation Safety Information

As GI antispasmodic

As GI antispasmodic
No published evidence of safety
Used in infants >1 month
Low levels anticipated in milk due to the drug’s properties
See summary for further information on anticholinergic affects
14th July 2016

For enuresis

For enuresis
Low levels anticipated in milk due to the drug's properties
No published evidence of safety
Monitor infant for anticholinergic effects, e.g. urinary retention, colic and constipation